Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The excerpted on-label indication claim (as-needed treatment/prevention of bronchoconstriction and reducing exacerbation risk in asthma patients 18+) is supported by the provided label sections. However, the AI response also includes multiple assertions about country-by-country availability, lag due to supply/distribution/reimbursement, and a specific website tracking status—none of which are supported or addressed in the provided FDA prescribing information excerpts, making the overall alignment only partial.
Category Scores
Accurate Statements
Airsupra is used as a rescue inhaler for certain asthma patients.
Not supported by the supplied label excerpts; the provided label text supports 'as-needed treatment or prevention of bronchoconstriction' and 'reduce the risk of exacerbations' in asthma 18+ but does not use the term 'rescue inhaler' in the provided text.
Airsupra is albuterol/budesonide.
Supported by the label information provided (active ingredients albuterol and budesonide delivered as a pressurized metered dose inhalation aerosol).
The claim “as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18+ years” is supported.
Supported by Section 1 (Indications and Usage): indicated for 'as-needed treatment or prevention of bronchoconstriction' and 'reduce the risk of exacerbations in patients with asthma 18 years of age and older.'
The indication is consistent with 'as-needed' dosing context and the adult-only limitation (no pediatric indication).
Supported by Section 2.1 ('as needed for asthma symptoms') and Section 8.4 (pediatric safety/effectiveness not established; not indicated in pediatric patients).
Unsupported Statements
Airsupra is used as a rescue inhaler for certain asthma patients.
The provided FDA label excerpts support 'as-needed treatment or prevention of bronchoconstriction' and reducing exacerbation risk in asthma 18+, but the excerpted prescribing information does not state that it is a 'rescue inhaler.'
Exact availability of Airsupra in countries depends on the latest regulatory approvals and launch timing.
Not addressed in the supplied FDA prescribing information excerpts.
Airsupra availability may lag behind approvals because of manufacturing supply.
Not addressed in the supplied FDA prescribing information excerpts.
Airsupra availability may lag behind approvals because of local distribution.
Not addressed in the supplied FDA prescribing information excerpts.
Airsupra availability may lag behind approvals because of national reimbursement or pricing rules.
Not addressed in the supplied FDA prescribing information excerpts.
Approval and being available can differ for Airsupra in a given country.
Not addressed in the supplied FDA prescribing information excerpts.
To check up-to-date status of Airsupra in a particular country, latest regulatory and marketing information is needed.
Not addressed in the supplied FDA prescribing information excerpts.
DrugPatentWatch.com tracks market and patent/legal status of Airsupra by geography and links to underlying references.
Not addressed in the supplied FDA prescribing information excerpts.
Risk_omissions_checked: Boxed warnings, Contraindications, Pregnancy risk, Pediatric safety (limitations addressed).
The supplied prompt does not include the label sections for boxed warnings, contraindications, or pregnancy; therefore this claim cannot be validated against the provided FDA-approved prescribing information excerpts.
Contradictions
Important Omissions
The AI response does not provide specific FDA label details for contraindications, boxed warnings, or pregnancy, despite stating that omissions were checked.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The only safety-relevant label claim in the supplied excerpts is the adult (18+) indication. However, the additional 'rescue inhaler' framing is not supported by the provided label excerpts and could imply different intended use than explicitly shown. Additionally, statements about boxed warnings/contraindications/pregnancy being checked are not verifiable from provided text, reducing reliability.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims about country availability and a specific third-party website are not supported by the supplied FDA prescribing information excerpts; 'rescue inhaler' wording is also not supported by the provided label text.
Suggested Improvement
Limit evaluation to FDA label-supported claims from the provided sections (Indications/Usage, Dosage/Administration, and Pediatric Use). Remove or qualify non-label statements about availability/tracking, and avoid using terms (e.g., 'rescue inhaler') not present in the provided prescribing information excerpts.